← All trials
NCT07304284
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Feb 28, 2027
- First posted
- Dec 26, 2025
- Last posted
- Dec 26, 2025
- Enrollment
- 2824
- Arms / groups
- 10 / —
- Source
- AACT · ctgov ingestion
Sponsors
- International Vaccine InstituteLead sponsor
- BioVacCollaborator
- International Vaccine InstituteOfficial
- Medical Research Council, South AfricaCollaborator
- Medical Research Council, South AfricaOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.